Eli Lilly and Company said on May 21, 2026, that its experimental drug retatrutide achieved strong results in a Phase-III clinical trial [1].

The results represent a potential shift in obesity treatment by offering weight loss levels that mirror bariatric surgery without the need for invasive procedures.

The multicenter global study, known as TRIUMPH-1, evaluated the efficacy of the triple-hormone receptor agonist for patients treating obesity and type-2 diabetes [3, 5]. Over the course of 80 weeks, all doses of the medication met both primary and secondary endpoints [3].

Data from the trial showed a maximum average weight loss of up to 28% of body weight [1]. Further analysis indicated that over 45% of participants achieved weight loss of approximately 30% [2]. These figures position the drug as a potent option for those struggling with severe obesity.

Beyond weight reduction, the drug demonstrated broad benefits for related comorbidities. The company said there were improvements in type-2 diabetes, sleep apnea, and arthritis among the trial participants [1].

While the efficacy data is strong, some analysts have questioned the safety profile of the drug due to adverse events [2]. Other reports have focused primarily on the drug's ability to deliver unprecedented weight loss [3].

Eli Lilly is now moving toward a regulatory filing to bring the treatment to market. The company said it intends to leverage these results to challenge existing weight-loss medications and expand its footprint in the metabolic health sector [1, 4].

“Over 45% of participants achieved weight loss of approximately 30%.”

The success of retatrutide signifies a transition from single or dual-hormone agonists to triple-hormone therapy in obesity treatment. By targeting three different receptors, the drug achieves higher weight loss percentages than many current predecessors. If approved, it could redefine the clinical standard for medical weight management and reduce the reliance on surgical interventions for chronic obesity.